Notably, tumour regressions were more profound and durable compared to afatinib (irreversible EGFR inhibitor) and cetuximab (anti-EGFR monoclonal antibody) in murine xenograft models of epidermoid carcinoma (A431) and HNSCC (FaDu) [161]. Here, EGFR is linked to head and neck squamous cell carcinoma.